Inclusion Criteria:

- Signed and dated, institutional review board (IRB) or independent ethics committee
(IEC)-approved informed consent form before any protocol-specific screening
procedures

- Previous histologic diagnosis of adenocarcinoma of the colon or rectum

- EGFR expression by immunohistochemical analysis (must be > or = 20% positive tumor
cells in prior tumor biopsy specimens)

Exclusion Criteria:

- Chemotherapy, radiotherapy, anticancer immunotherapy, or investigational agents
within 4 weeks of treatment day 1 (6 weeks if the previous regimen included
mitomycin or nitrosoureas).

- Prior epidermal growth factor receptor-targeting therapy

- Known central nervous system (CNS) metastases